img1
  • Press Release Healthcare

    The ‘Biosimilar Action Plan’ is another FDA move designed to chase value based pricing

    On Wednesday (18 July) the FDA unveiled the ‘Biosimilar Action Plan’ (BAP), which aims to promote the development and accessibility of biosimilars in the US healthcare market. Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this means for the price of branded biologic molecules: “We believe...

img1
  • Press Release Healthcare

    J&J’s HIV therapeutic Symtuza on track for US launch in 2018 after FDA approval

    Following the news (Tuesday 17th July) that J&J’s HIV therapeutic, Symtuza, has been granted marketing approval by the FDA, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “This news puts J&J’s Symtuza on track to launch in the US later this year, where it is predicted to...

img1

Filter Media:

Reset

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF